1887

Abstract

Sulfated polyanions, including pentosan polysulfate (PPS) and heparan mimetics, number among the most effective drugs that have been used in experimental models of prion disease and are presumed to act in competition with endogenous heparan sulfate proteoglycans as co-receptors for prion protein (PrP) on the cell surface. PPS has been shown to prolong the survival of animals after intracerebral perfusion and is in limited use for the experimental treatment of human transmissible spongiform encephalopathies (TSEs). Here, PPS is compared with CR36, a new heparan mimetic. , CR36 was more efficient than PPS in reducing PrP in scrapie-infected cell cultures and showed long-lasting activity. , CR36 showed none of the acute toxicity observed with PPS and reduced PrP accumulation in spleens, but had only a marginal effect on the survival time of mice infected with bovine spongiform encephalopathy. In contrast, mice treated with PPS that survived the initial toxic mortality had no detectable PrP in the spleens and lived 185 days longer than controls (+55 %). These results show, once again, that anti-TSE drugs cannot be encouraged for human therapeutic trials solely on the basis of or observations, but must first be subjected to animal studies.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.82286-0
2007-03-01
2024-03-28
Loading full text...

Full text loading...

/deliver/fulltext/jgv/88/3/1062.html?itemId=/content/journal/jgv/10.1099/vir.0.82286-0&mimeType=html&fmt=ahah

References

  1. Adjou K. T., Simoneau S., Sales N., Lamoury F., Dormont D., Papy-Garcia D., Barritault D., Deslys J. P., Lasmezas C. I. 2003; A novel generation of heparan sulfate mimetics for the treatment of prion diseases. J Gen Virol 84:2595–2603 [CrossRef]
    [Google Scholar]
  2. Barret A., Tagliavini F., Forloni G., Bate C., Salmona M., Colombo L., De Luigi A., Limido L., Suardi S. other authors 2003; Evaluation of quinacrine treatment for prion diseases. J Virol 77:8462–8469 [CrossRef]
    [Google Scholar]
  3. Ben-Zaken O., Tzaban S., Tal Y., Horonchik L., Esko J. D., Vlodavsky I., Taraboulos A. 2003; Cellular heparan sulfate participates in the metabolism of prions. J Biol Chem 278:40041–40049 [CrossRef]
    [Google Scholar]
  4. Beringue V., Adjou K. T., Lamoury F., Maignien T., Deslys J. P., Race R., Dormont D. 2000; Opposite effects of dextran sulfate 500, the polyene antibiotic MS-8209, and Congo red on accumulation of the protease-resistant isoform of PrP in the spleens of mice inoculated intraperitoneally with the scrapie agent. J Virol 74:5432–5440 [CrossRef]
    [Google Scholar]
  5. Blanquaert F., Saffar J. L., Colombier M. L., Carpentier G., Barritault D., Caruelle J. P. 1995; Heparan-like molecules induce the repair of skull defects. Bone 17:499–506 [CrossRef]
    [Google Scholar]
  6. Brimacombe D. B., Bennett A. D., Wusteman F. S., Gill A. C., Dann J. C., Bostock C. J. 1999; Characterization and polyanion-binding properties of purified recombinant prion protein. Biochem J 342:605–613 [CrossRef]
    [Google Scholar]
  7. Brown P. 2002; Drug therapy in human and experimental transmissible spongiform encephalopathy. Neurology 58:1720–1725 [CrossRef]
    [Google Scholar]
  8. Cashman N. R., Caughey B. 2004; Prion diseases – close to effective therapy?. Nat Rev Drug Discov 3:874–884 [CrossRef]
    [Google Scholar]
  9. Caughey B., Raymond G. J. 1993; Sulfated polyanion inhibition of scrapie-associated PrP accumulation in cultured cells. J Virol 67:643–650
    [Google Scholar]
  10. Collins S. J., Lewis V., Brazier M., Hill A. F., Fletcher A., Masters C. L. 2002; Quinacrine does not prolong survival in a murine Creutzfeldt-Jakob disease model. Ann Neurol 52:503–506 [CrossRef]
    [Google Scholar]
  11. Deleault N. R., Geoghegan J. C., Nishina K., Kascsak R., Williamson R. A., Supattapone S. 2005; Protease-resistant prion protein amplification reconstituted with partially purified substrates and synthetic polyanions. J Biol Chem 280:26873–26879 [CrossRef]
    [Google Scholar]
  12. Desgranges P., Barbaud C., Caruelle J. P., Barritault D., Gautron J. 1999; A substituted dextran enhances muscle fiber survival and regeneration in ischemic and denervated rat EDL muscle. FASEB J 13:761–766
    [Google Scholar]
  13. Diringer H., Ehlers B. 1991; Chemoprophylaxis of scrapie in mice. J Gen Virol 72:457–460 [CrossRef]
    [Google Scholar]
  14. Doh-ura K., Ishikawa K., Murakami-Kubo I., Sasaki K., Mohri S., Race R., Iwaki T. 2004; Treatment of transmissible spongiform encephalopathy by intraventricular drug infusion in animal models. J Virol 78:4999–5006 [CrossRef]
    [Google Scholar]
  15. Farquhar C., Dickinson A., Bruce M. 1999; Prophylactic potential of pentosan polysulphate in transmissible spongiform encephalopathies. Lancet 353:117
    [Google Scholar]
  16. Furukawa H., Takahashi M., Nakajima M., Yamada T. 2002; Prospects of the therapeutic approaches to Creutzfeldt-Jakob disease: a clinical trial of antimalarial, quinacrine. Nippon Rinsho 60:1649–1657 (in Japanese
    [Google Scholar]
  17. Gabizon R., Meiner Z., Halimi M., Ben-Sasson S. A. 1993; Heparin-like molecules bind differentially to prion-proteins and change their intracellular metabolic fate. J Cell Physiol 157:319–325 [CrossRef]
    [Google Scholar]
  18. Gonzalez-Iglesias R., Pajares M. A., Ocal C., Espinosa J. C., Oesch B., Gasset M. 2002; Prion protein interaction with glycosaminoglycan occurs with the formation of oligomeric complexes stabilized by Cu(II) bridges. J Mol Biol 319:527–540 [CrossRef]
    [Google Scholar]
  19. Graner E., Mercadante A. F., Zanata S. M., Martins V. R., Jay D. G., Brentani R. R. 2000; Laminin-induced PC-12 cell differentiation is inhibited following laser inactivation of cellular prion protein. FEBS Lett 482:257–260 [CrossRef]
    [Google Scholar]
  20. Grassi J., Comoy E., Simon S., Creminon C., Frobert Y., Trapmann S., Schimmel H., Hawkins S. A., Moynagh J. other authors 2001; Rapid test for the preclinical postmortem diagnosis of BSE in central nervous system tissue. Vet Rec 149:577–582 [CrossRef]
    [Google Scholar]
  21. Horonchik L., Tzaban S., Ben-Zaken O., Yedidia Y., Rouvinski A., Papy-Garcia D., Barritault D., Vlodavsky I., Taraboulos A. 2005; Heparan sulfate is a cellular receptor for purified infectious prions. J Biol Chem 280:17062–17067 [CrossRef]
    [Google Scholar]
  22. Hundt C., Peyrin J. M., Haik S., Gauczynski S., Leucht C., Rieger R., Riley M. L., Deslys J. P., Dormont D. other authors 2001; Identification of interaction domains of the prion protein with its 37-kDa/67-kDa laminin receptor. EMBO J 20:5876–5886 [CrossRef]
    [Google Scholar]
  23. Kobayashi Y., Hirata K., Tanaka H., Yamada T. 2003; Quinacrine administration to a patient with Creutzfeldt-Jakob disease who received a cadaveric dura mater graft – an EEG evaluation. Rinsho Shinkeigaku 43:403–408 (in Japanese
    [Google Scholar]
  24. Korth C., May B. C., Cohen F. E., Prusiner S. B. 2001; Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc Natl Acad Sci U S A 98:9836–9841 [CrossRef]
    [Google Scholar]
  25. Kuwahara C., Takeuchi A. M., Nishimura T., Haraguchi K., Kubosaki A., Matsumoto Y., Saeki K., Yokoyama T., Itohara S., Onodera T. 1999; Prions prevent neuronal cell-line death. Nature 400:225–226 [CrossRef]
    [Google Scholar]
  26. Ladogana A., Casaccia P., Ingrosso L., Cibati M., Salvatore M., Xi Y. G., Masullo C., Pocchiari M. 1992; Sulphate polyanions prolong the incubation period of scrapie-infected hamsters. J Gen Virol 73:661–665 [CrossRef]
    [Google Scholar]
  27. Lasmezas C. I., Deslys J. P., Robain O., Jaegly A., Beringue V., Peyrin J. M., Fournier J. G., Hauw J. J., Rossier J., Dormont D. 1997; Transmission of the BSE agent to mice in the absence of detectable abnormal prion protein. Science 275:402–405 [CrossRef]
    [Google Scholar]
  28. Llewelyn C. A., Hewitt P. E., Knight R. S., Amar K., Cousens S., Mackenzie J., Will R. G. 2004; Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet 363:417–421 [CrossRef]
    [Google Scholar]
  29. Mange A., Nishida N., Milhavet O., McMahon H. E., Casanova D., Lehmann S. 2000; Amphotericin B inhibits the generation of the scrapie isoform of the prion protein in infected cultures. J Virol 74:3135–3140 [CrossRef]
    [Google Scholar]
  30. Meddahi A., Blanquaert F., Saffar J. L., Colombier M. L., Caruelle J. P., Josefonvicz J., Barritault D. 1994; New approaches to tissue regeneration and repair. Pathol Res Pract 190:923–928 [CrossRef]
    [Google Scholar]
  31. Nakajima M., Yamada T., Kusuhara T., Furukawa H., Takahashi M., Yamauchi A., Kataoka Y. 2004; Results of quinacrine administration to patients with Creutzfeldt-Jakob disease. Dement Geriatr Cogn Disord 17:158–163 [CrossRef]
    [Google Scholar]
  32. Papy-Garcia D., Barbosa I., Duchesnay A., Saadi S., Caruelle J. P., Barritault D., Martelly I. 2002; Glycosaminoglycan mimetics (RGTA) modulate adult skeletal muscle satellite cell proliferation in vitro. J Biomed Mater Res 62:46–55 [CrossRef]
    [Google Scholar]
  33. Peden A. H., Head M. W., Ritchie D. L., Bell J. E., Ironside J. W. 2004; Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet 364:527–529 [CrossRef]
    [Google Scholar]
  34. Priola S. A., Caughey B., Raymond G. J., Chesebro B. 1994; Prion protein and the scrapie agent: in vitro studies in infected neuroblastoma cells. Infect Agents Dis 3:54–58
    [Google Scholar]
  35. Schmitt-Ulms G., Legname G., Baldwin M. A., Ball H. L., Bradon N., Bosque P. J., Crossin K. L., Edelman G. M., DeArmond S. J. other authors 2001; Binding of neural cell adhesion molecules (N-CAMs) to the cellular prion protein. J Mol Biol 314:1209–1225 [CrossRef]
    [Google Scholar]
  36. Schonberger O., Horonchik L., Gabizon R., Papy-Garcia D., Barritault D., Taraboulos A. 2003; Novel heparan mimetics potently inhibit the scrapie prion protein and its endocytosis. Biochem Biophys Res Commun 312:473–479 [CrossRef]
    [Google Scholar]
  37. Shyng S. L., Lehmann S., Moulder K. L., Harris D. A. 1995; Sulfated glycans stimulate endocytosis of the cellular isoform of the prion protein, PrPC, in cultured cells. J Biol Chem 270:30221–30229 [CrossRef]
    [Google Scholar]
  38. Spielhaupter C., Schatzl H. M. 2001; PrPC directly interacts with proteins involved in signaling pathways. J Biol Chem 276:44604–44612 [CrossRef]
    [Google Scholar]
  39. Todd N. V., Morrow J., Doh-ura K., Dealler S., O'Hare S., Farling P., Duddy M., Rainov N. G. 2005; Cerebroventricular infusion of pentosan polysulphate in human variant Creutzfeldt-Jakob disease. J Infect 50:394–396 [CrossRef]
    [Google Scholar]
  40. Warner R. G., Hundt C., Weiss S., Turnbull J. E. 2002; Identification of the heparan sulfate binding sites in the cellular prion protein. J Biol Chem 277:18421–18430 [CrossRef]
    [Google Scholar]
  41. Weissmann C., Aguzzi A. 2005; Approaches to therapy of prion diseases. Annu Rev Med 56:321–344 [CrossRef]
    [Google Scholar]
  42. Wong C., Xiong L. W., Horiuchi M., Raymond L., Wehrly K., Chesebro B., Caughey B. 2001; Sulfated glycans and elevated temperature stimulate PrP(Sc)-dependent cell-free formation of protease-resistant prion protein. EMBO J 20:377–386 [CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.82286-0
Loading
/content/journal/jgv/10.1099/vir.0.82286-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error